Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis:Is there anything new under the sun?  

作　　者：Peter Laszlo Lakatos 

机构地区：[1]1st Department of Medicine,Semmelweis University

出　　处：《World Journal of Gastroenterology》2009年第15期1799-1804,共6页世界胃肠病学杂志（英文版）

摘　　要：5-aminosalicylate(5-ASA)agents remain the mainstay treatment in ulcerative colitis(UC).A number of oral 5-ASA agents are commercially available,including azobond pro-drugs,as well as delayed-and controlledrelease forms of mesalazine.However,poor adherence due to frequent daily dosing and a large number of tablets has been shown to be an important barrier to successful management of patients with UC.Recently, new,once-daily formulations of mesalazine,including the unique multi-matrix delivery system and mesalazine granules,were proven to be efficacious in inducing and maintaining remission in mild-to-moderate UC,with a good safety profile comparable to that of other oral mesalazine formulations.In addition,they offer the advantage of a low pill burden and might contribute to increased long-term compliance and treatment success in clinical practice.This editorial summarizes the available literature on the short-and medium-term efficacy and safety of the new once-daily mesalazine formulations.5-aminosalicylate （5-ASA） agents remain the mainstay treatment in ulcerative colitis （UC）. A number of oral 5-ASA agents are commercially available, including azo- bond pro-drugs, as well as delayed- and controlled- release forms of mesalazine. However, poor adherence due to frequent daily dosing and a large number of tablets has been shown to be an important barrier to successful management of patients with UC. Recently, new, once-daily formulations of mesalazine, including the unique multi-matrix delivery system and mesalazine granules, were proven to be efficacious in inducing and maintaining remission in mild-to-moderate UC, with a good safety profile comparable to that of other oral mesalazine formulations. In addition, they offer the advantage of a low pill burden and might contribute to increased long-term compliance and treatment success in clinical practice. This editorial summarizes the available literature on the short- and medium-term efficacy and safety of the new once-daily mesalazine formulations.

关 键 词：Ulcerative colitis 5-aminosalicylate MESALAZINE Multi matrix system Therapy ONCE-DAILY Compliance 

分 类 号：R574.62[医药卫生—消化系统]